Farris Foundation Donates $1.1 Million to Fund TSRI Graduate Fellowship in Florida
November 8, 2016
JUPITER, FL, November 8, 2016 – The Celia Lipton Farris and Victor W. Farris Foundation has made a $1.135 million gift to The Scripps Research Institute (TSRI) to create the Farris Foundation Endowed Graduate Fellowship on the Jupiter, Florida campus.
“I want to thank the Farris Foundation for its generous gift to support our graduate program,” said TSRI President Peter Schultz. “Gifts like this will help train the next generation of scientists who are critical to the future of biomedical research—and to build a lasting legacy of scientific excellence.”
The new Farris Foundation Endowed Graduate Fellowship will provide annual support for doctoral students at Scripps Florida in perpetuity.
“Our gift is an investment in the continued strength of biomedical research at Scripps Florida,” said Christine Koehn, executive director of the Farris Foundation, “so that young scholars will be able to reach their full potential as world-class scientists.”
TSRI’s graduate program is consistently rated by U.S. News and World Report as in the top 10 of its kind in the nation for chemistry and biology. Scripps Florida established a branch of the graduate program in 2005; the campus has since graduated 28 PhDs, and 49 doctoral students are currently enrolled.
The Celia Lipton Farris and Victor W. Farris Foundation, created in 1986 by a merger of the Victor W. Farris Foundation and the Celia Lipton Farris Foundation, seeks to support projects that provide the structure, encouragement and incentive that enable people to help themselves lead more successful, inspired and fulfilling lives.
More information on The Celia Lipton Farris and Victor W. Farris Foundation and TSRI’s graduate program is available on their respective websites.
Calibr-Skaggs advances CLF065, a regenerative GLP-2 therapy, into two Phase 2 IBD studies
CLF065, a long-acting, once-weekly GLP-2 receptor agonist, advances in two inflammatory bowel disease indications. The studies aim to bring a regenerative treatment option to patients living with IBD, who currently have few therapies that repair the damaged intestinal lining at the root of their disease.
Advancing the vision: An experiment in rethinking the nonprofit biomedical research model
In his Front Row lecture, President and CEO Pete Schultz highlighted the progress Scripps Research has made in pioneering a new model for non-profit biomedical research. He described how integrating basic science and translational research under one roof is accelerating next-generation medicines—from new immunotherapies for cancer and innovative medicines for infectious disease to regenerative treatments for heart, lung and intestinal tissues. At a time of uncertainty in federal science funding, this model isn't only advancing human health but also helping to generate sustainable support for innovative scientific research and for training the next generation of scientific leaders.
Viome and Scripps Research partner to develop first at-home RNA screening test to prevent colon cancer before it strikes
First-of-its-kind 1,000-patient clinical study will use RNA-based stool and saliva tests to detect colon polyps — early warning signs of colorectal cancer — before they become cancerous.Study aims to enhance colorectal cancer prevention by identifying polyp molecular signals, offering improved sensitivity over at-home DNA tests, which have limited ability to detect precancerous lesions.
Enzyme engineering opens door to novel therapies for Parkinson’s, cancers and other hard-to-target protein diseases
Researchers reprogrammed a botulinum toxin protease to selectively break down disease-causing proteins in human cells, providing proof of concept for developing new therapies for a wide range of illnesses.